Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumor Malignancy × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 23 Leukemia, Myeloid, Acute 21 Recurrence 12 Sarcoma 6 Lymphoma, Large B-Cell, Diffuse 5 Neurofibrosarcoma 4 Neoplasms, Plasma Cell 4 Neoplasm Metastasis 4 Lymphoma 4 Myelodysplastic Syndromes 3 Lymphoma, Non-Hodgkin 3 Lymphoma, B-Cell 3 Thymoma 2 Rhabdoid Tumor 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Neoplasms 2 Lymphoma, Mantle-Cell 2 Liposarcoma 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Biphenotypic, Acute 2 Leukemia 2 Congenital Abnormalities 2 Carcinoma 2 Wilms Tumor 1 Waldenstrom Macroglobulinemia 1 Vascular Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solitary Fibrous Tumors 1

Interventions

selinexor 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Hackensack Meridian Health

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡